Actively Recruiting
Psilocybin-Assisted Therapy for Intergenerational Trauma
Led by Rachel Yehuda · Updated on 2025-09-08
100
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.
CONDITIONS
Official Title
Psilocybin-Assisted Therapy for Intergenerational Trauma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age at least 18 years old at time of signing the informed consent
- Biological child of at least one parent who directly survived or escaped a genocide
- Meets diagnostic criteria for a depressive or anxiety disorder
- Capable of providing informed consent and complying with study procedures
- Currently using or agreeing to use adequate contraceptive methods
- Fluent in speaking and reading English
- Able to swallow pills
- Agrees to have study visits recorded with audio and video
- Able to provide a contact person reachable by investigators if participant becomes unwell or unreachable
- Agrees to inform investigators within 48 hours of any medical conditions and procedures
- Agrees to release outside medical and psychiatric records
- Must not participate in any other interventional clinical trials during the study
- Must commit to medication dosing, therapy, and all study procedures
You will not qualify if you...
- Unable to give adequate informed consent
- Was directly exposed to or survived a genocide
- Has any medical condition or significant clinical finding making psilocybin unsafe
- Has acute, severe, or unstable medical illness
- Has history of stroke or Transient Ischemic Attack (TIA)
- Has had psychiatric hospitalization within last 6 months
- Has current serious suicide risk
- Unable or unwilling to safely taper off prohibited psychiatric medications
- Abusing alcohol or other substances
- Has used psychedelics within 3 months of enrollment
- Pregnant, nursing, or able to become pregnant without effective contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Parsons Research Center for Psychedelic Healing
New York, New York, United States, 10025
Actively Recruiting
Research Team
L
Lauren Lepow, MD, PhD
CONTACT
E
Evelyn Alkin, MA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here